{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:10:06Z","timestamp":1793830206713,"version":"4.6.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012164","name":"National High-tech Research and Development Program","doi-asserted-by":"publisher","award":["2015AA020701"],"award-info":[{"award-number":["2015AA020701"]}],"id":[{"id":"10.13039\/501100012164","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200609"],"award-info":[{"award-number":["82200609"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Predictive markers for fecal microbiota transplantation (FMT) outcomes in patients with active ulcerative colitis (UC) are poorly defined. We aimed to investigate changes in gut microbiota pre- and post-FMT and to assess the potential value in determining the total copy number of fecal bacterial siderophore genes in predicting FMT responsiveness.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with active UC (Mayo score\u2009\u2265\u20093) who had undergone two FMT procedures were enrolled. Fecal samples were collected before and 8\u00a0weeks after each FMT session. Patients were classified into clinical response and non-response groups, based on their Mayo scores. The fecal microbiota profile was accessed using metagenomic sequencing, and the total siderophore genes copy number via quantitative real-time polymerase chain reaction. Additionally, we examined the association between the total siderophore genes copy number and FMT efficacy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Seventy patients with UC had undergone FMT. The clinical response and remission rates were 50% and 10% after the first FMT procedure, increasing to 72.41% and 27.59% after the second FMT. The cumulative clinical response and clinical remission rates were 72.86% and 25.71%. Compared with baseline, the response group showed a significant increase in <jats:italic>Faecalibacterium<\/jats:italic>, and decrease in <jats:italic>Enterobacteriaceae<\/jats:italic>, consisted with the changes of the total bacterial siderophore genes copy number after the second FMT (1889.14 vs. 98.73 copies\/ng, P\u2009&lt;\u20090.01). Virulence factor analysis showed an enriched iron uptake system, especially bacterial siderophores, in the pre-FMT response group, with a greater contribution from <jats:italic>Escherichia coli<\/jats:italic>. The total baseline copy number was significantly higher in the response group than non-response group (1889.14 vs. 94.86 copies\/ng, P\u2009&lt;\u20090.01). A total baseline copy number cutoff value of 755.88 copies\/ng showed 94.7% specificity and 72.5% sensitivity in predicting FMT responsiveness.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>A significant increase in <jats:italic>Faecalibacterium<\/jats:italic>, and decrease in <jats:italic>Enterobacteriaceae<\/jats:italic> and the total fecal siderophore genes copy number were observed in responders after\u00a0FMT. The siderophore genes and its encoding bacteria may be of predictive value for the clinical responsiveness of FMT to active ulcerative colitis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12967-024-05419-w","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T10:02:05Z","timestamp":1719223325000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Siderophore-harboring gut bacteria and fecal siderophore genes for predicting the responsiveness of fecal microbiota transplantation for active ulcerative colitis"],"prefix":"10.1186","volume":"22","author":[{"given":"Jingshuang","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanzhou","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zikai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0361-7674","authenticated-orcid":false,"given":"Yunsheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,24]]},"reference":[{"key":"5419_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.06.030","author":"MJ Buie","year":"2023","unstructured":"Buie MJ, Quan J, Windsor JW, et al. Global hospitalisation trends for Crohn\u2019s disease and ulcerative colitis in the 21st century: a systematic review with temporal analyses. Clin Gastroenterol Hepatol. 2023. https:\/\/doi.org\/10.1016\/j.cgh.2022.06.030.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5419_CR2","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2021.1840976","author":"SC Wei","year":"2021","unstructured":"Wei SC, Sollano J, Hui YT, et al. Epidemiology, burden of disease, and unmet needs in the treatment of ulcerative colitis in Asia. Exp Rev Gastroenterol Hepatol. 2021. https:\/\/doi.org\/10.1080\/17474124.2021.1840976.","journal-title":"Exp Rev Gastroenterol Hepatol"},{"key":"5419_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)00966-2","author":"C Le Berre","year":"2023","unstructured":"Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis. Lancet (London, England). 2023. https:\/\/doi.org\/10.1016\/s0140-6736(23)00966-2.","journal-title":"Lancet (London, England)"},{"key":"5419_CR4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.12.009","author":"CW Ko","year":"2019","unstructured":"Ko CW, Singh S, Feuerstein JD, et al. AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis. Gastroenterology. 2019. https:\/\/doi.org\/10.1053\/j.gastro.2018.12.009.","journal-title":"Gastroenterology"},{"key":"5419_CR5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.006","author":"S Singh","year":"2020","unstructured":"Singh S, Allegretti JR, Siddique SM, et al. AGA technical review on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.006.","journal-title":"Gastroenterology"},{"key":"5419_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00377-0","author":"JS Lasa","year":"2022","unstructured":"Lasa JS, Olivera PA, Danese S, et al. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2022. https:\/\/doi.org\/10.1016\/S2468-1253(21)00377-0.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"5419_CR7","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1146\/annurev-med-052919-120048","volume":"72","author":"RP Hirten","year":"2021","unstructured":"Hirten RP, Sands BE. New therapeutics for ulcerative colitis. Ann Rev Med. 2021;72:199\u2013213. https:\/\/doi.org\/10.1146\/annurev-med-052919-120048.","journal-title":"Ann Rev Med"},{"key":"5419_CR8","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-111717-122956","author":"RE Ooijevaar","year":"2019","unstructured":"Ooijevaar RE, Terveer EM, Verspaget HW, et al. Clinical application and potential of faecal microbiota transplantation. Ann Rev Med. 2019. https:\/\/doi.org\/10.1146\/annurev-med-111717-122956.","journal-title":"Ann Rev Med"},{"key":"5419_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14201","author":"MN Quraishi","year":"2017","unstructured":"Quraishi MN, Widlak M, Bhala N, et al. Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment pharmacol Ther. 2017. https:\/\/doi.org\/10.1111\/apt.14201.","journal-title":"Aliment pharmacol Ther"},{"key":"5419_CR10","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000001228","author":"N Narula","year":"2017","unstructured":"Narula N, Kassam Z, Yuan Y, et al. Systematic review and meta-analysis: fecal microbiota transplantation for treatment of active ulcerative colitis. Inflamm Bowel Dis. 2017. https:\/\/doi.org\/10.1097\/MIB.0000000000001228.","journal-title":"Inflamm Bowel Dis"},{"key":"5419_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-41182-6","author":"J Feng","year":"2023","unstructured":"Feng J, Chen Y, Liu Y, et al. Efficacy and safety of faecal microbiota transplantation in the treatment of ulcerative colitis: a systematic review and meta-analysis. Sci Rep. 2023. https:\/\/doi.org\/10.1038\/s41598-023-41182-6.","journal-title":"Sci Rep"},{"key":"5419_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157259","author":"Y Shi","year":"2016","unstructured":"Shi Y, Dong Y, Huang W, et al. Faecal microbiota transplantation for ulcerative colitis: a systematic review and meta-analysis. PLoS ONE. 2016. https:\/\/doi.org\/10.1371\/journal.pone.0157259.","journal-title":"PLoS ONE"},{"key":"5419_CR13","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/8941340","author":"H Fang","year":"2018","unstructured":"Fang H, Fu L, Wang J. Protocol for fecal microbiota transplantation in inflammatory bowel disease: a systematic review and meta-analysis. Biomed Res Int. 2018. https:\/\/doi.org\/10.1155\/2018\/8941340.","journal-title":"Biomed Res Int"},{"key":"5419_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)30182-4","author":"S Paramsothy","year":"2017","unstructured":"Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet (London, England). 2017. https:\/\/doi.org\/10.1016\/s0140-6736(17)30182-4.","journal-title":"Lancet (London, England)"},{"key":"5419_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.742255","author":"R Ren","year":"2021","unstructured":"Ren R, Gao X, Shi Y, et al. Long-term efficacy of low-intensity single donor faecal microbiota transplantation in ulcerative colitis and outcome-specific gut bacteria. Front Microbiol. 2021. https:\/\/doi.org\/10.3389\/fmicb.2021.742255.","journal-title":"Front Microbiol"},{"key":"5419_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133925","author":"CJ Damman","year":"2015","unstructured":"Damman CJ, Brittnacher MJ, Westerhoff M, et al. Low level engraftment and improvement following a single colonoscopic administration of faecal microbiota to patients with ulcerative colitis. PLoS ONE. 2015. https:\/\/doi.org\/10.1371\/journal.pone.0133925.","journal-title":"PLoS ONE"},{"key":"5419_CR17","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.04152-22","author":"Q Chen","year":"2023","unstructured":"Chen Q, Fan Y, Zhang B, et al. Capsulized faecal microbiota transplantation induces remission in patients with ulcerative colitis by gut microbial colonization and metabolite regulation. Microbiol Spectrum. 2023. https:\/\/doi.org\/10.1128\/spectrum.04152-22.","journal-title":"Microbiol Spectrum"},{"key":"5419_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv203","author":"S Vermeire","year":"2016","unstructured":"Vermeire S, Joossens M, Verbeke K, et al. Donor species richness determines faecal microbiota transplantation success in inflammatory bowel disease. J Crohns Colitis. 2016. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjv203.","journal-title":"J Crohns Colitis"},{"key":"5419_CR19","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.12.001","author":"S Paramsothy","year":"2019","unstructured":"Paramsothy S, Nielsen S, Kamm MA, et al. Specific bacteria and metabolites associated with response to faecal microbiota transplantation in patients with ulcerative colitis. Gastroenterology. 2019. https:\/\/doi.org\/10.1053\/j.gastro.2018.12.001.","journal-title":"Gastroenterology"},{"key":"5419_CR20","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2022.2100197","author":"R He","year":"2022","unstructured":"He R, Li P, Wang J, et al. The interplay of gut microbiota between donors and recipients determines the efficacy of faecal microbiota transplantation. Gut Microbes. 2022. https:\/\/doi.org\/10.1080\/19490976.2022.2100197.","journal-title":"Gut Microbes"},{"key":"5419_CR21","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001725","author":"Q Li","year":"2020","unstructured":"Li Q, Zhang T, Ding X, et al. Enhancing patient adherence to faecal microbiota transplantation maintains the long-term clinical effects in ulcerative colitis. Eur J Gastroenterol Hepatol. 2020. https:\/\/doi.org\/10.1097\/MEG.0000000000001725.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"5419_CR22","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2023.2185476","author":"Y Liu","year":"2023","unstructured":"Liu Y, Ji X, Huang Y, et al. Older patients benefit more from sequential courses of washed microbiota transplantation than younger population with ulcerative colitis. Scand J Gastroenterol. 2023. https:\/\/doi.org\/10.1080\/00365521.2023.2185476.","journal-title":"Scand J Gastroenterol"},{"key":"5419_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2020.08.006","author":"YW Cheng","year":"2020","unstructured":"Cheng YW, Fischer M. Faecal microbiota transplantation for ulcerative colitis. Are we ready for primetime? Gastroenterol Clin N Am. 2020. https:\/\/doi.org\/10.1016\/j.gtc.2020.08.006.","journal-title":"Gastroenterol Clin N Am"},{"key":"5419_CR24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0630018100","author":"KN Raymond","year":"2003","unstructured":"Raymond KN, Dertz EA, Kim SS. Enterobactin: an archetype for microbial iron transport. Proc Natl Acad Sci USA. 2003. https:\/\/doi.org\/10.1073\/pnas.0630018100.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5419_CR25","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2018.1546519","author":"P Saha","year":"2019","unstructured":"Saha P, Xiao X, Yeoh BS, et al. The bacterial siderophore enterobactin confers survival advantage to Salmonella in macrophages. Gut Microbes. 2019. https:\/\/doi.org\/10.1080\/19490976.2018.1546519.","journal-title":"Gut Microbes"},{"key":"5419_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s10534-009-9217-4","author":"SI M\u00fcller","year":"2009","unstructured":"M\u00fcller SI, Valdebenito M, Hantke K. Salmochelin, the long-overlooked catecholate siderophore of Salmonella. Biometals. 2009. https:\/\/doi.org\/10.1007\/s10534-009-9217-4.","journal-title":"Biometals"},{"key":"5419_CR27","doi-asserted-by":"publisher","DOI":"10.1128\/iai.00430-15","author":"TA Russo","year":"2015","unstructured":"Russo TA, Olson R, MacDonald U, et al. Aerobactin, but not yersiniabactin, salmochelin, or enterobactin, enables the growth\/survival of hypervirulent (hypermucoviscous) Klebsiella pneumoniae ex vivo and in vivo. Infect Immun. 2015. https:\/\/doi.org\/10.1128\/iai.00430-15.","journal-title":"Infect Immun"},{"key":"5419_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.699913","author":"C Li","year":"2021","unstructured":"Li C, Pan D, Li M, et al. Aerobactin-mediated iron acquisition enhances biofilm formation, oxidative stress resistance, and virulence of Yersinia pseudotuberculosis. Front Microbiol. 2021. https:\/\/doi.org\/10.3389\/fmicb.2021.699913.","journal-title":"Front Microbiol"},{"key":"5419_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22073512","author":"G Dalmasso","year":"2021","unstructured":"Dalmasso G, Nguyen HTT, Fa\u00efs T, et al. Yersiniabactin siderophore of Crohn\u2019s disease-associated adherent-invasive Escherichia coli is involved in autophagy activation in host cells. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22073512.","journal-title":"Int J Mol Sci"},{"key":"5419_CR30","doi-asserted-by":"publisher","DOI":"10.1128\/iai.00587-19","author":"M Ellermann","year":"2019","unstructured":"Ellermann M, Gharaibeh RZ, Fulbright L, et al. Yersiniabactin-producing adherent\/invasive Escherichia coli promotes inflammation-associated fibrosis in gnotobiotic Il10(-\/-) mice. Infect Immun. 2019. https:\/\/doi.org\/10.1128\/iai.00587-19.","journal-title":"Infect Immun"},{"key":"5419_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106661","author":"Y Wang","year":"2020","unstructured":"Wang Y, Ren R, Sun G, et al. Pilot study of cytokine changes evaluation after faecal microbiota transplantation in patients with ulcerative colitis. Int Immunopharmacol. 2020. https:\/\/doi.org\/10.1016\/j.intimp.2020.106661.","journal-title":"Int Immunopharmacol"},{"key":"5419_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.082909","author":"J Satsangi","year":"2006","unstructured":"Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006. https:\/\/doi.org\/10.1136\/gut.2005.082909.","journal-title":"Gut"},{"key":"5419_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318484","author":"CA Lamb","year":"2019","unstructured":"Lamb CA, Kennedy NA, Raine T, et al. British society of gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019. https:\/\/doi.org\/10.1136\/gutjnl-2019-318484.","journal-title":"Gut"},{"key":"5419_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.12994","author":"Inflammatory Bowel Disease Group, Chinese Society of Gastroenterology, Chinese Medical Association","year":"2021","unstructured":"Inflammatory Bowel Disease Group, Chinese Society of Gastroenterology, Chinese Medical Association. Chinese consensus on diagnosis and treatment in inflammatory bowel disease (2018, Beijing). J Dig Dis. 2021. https:\/\/doi.org\/10.1111\/1751-2980.12994.","journal-title":"J Dig Dis"},{"key":"5419_CR35","doi-asserted-by":"publisher","DOI":"10.1039\/c4mt00333k","author":"VI Holden","year":"2015","unstructured":"Holden VI, Bachman MA. Diverging roles of bacterial siderophores during infection. Metallomics. 2015. https:\/\/doi.org\/10.1039\/c4mt00333k.","journal-title":"Metallomics"},{"key":"5419_CR36","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v27.i28.4722","author":"XX He","year":"2021","unstructured":"He XX, Li YH, Yan PG, et al. Relationship between clinical features and intestinal microbiota in Chinese patients with ulcerative colitis. World J Gastroenterol. 2021. https:\/\/doi.org\/10.3748\/wjg.v27.i28.4722.","journal-title":"World J Gastroenterol"},{"key":"5419_CR37","doi-asserted-by":"publisher","DOI":"10.1128\/mSystems.00188-17","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, Xu ZZ, He Y, et al. Gut microbiota offers universal biomarkers across ethnicity in inflammatory bowel disease diagnosis and infliximab response prediction. mSystems. 2018. https:\/\/doi.org\/10.1128\/mSystems.00188-17.","journal-title":"mSystems."}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05419-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-024-05419-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05419-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T10:04:57Z","timestamp":1719223497000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-024-05419-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,24]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5419"],"URL":"https:\/\/doi.org\/10.1186\/s12967-024-05419-w","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,24]]},"assertion":[{"value":"22 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the PLA General Hospital (S2016-129\u201301, S2016-130\u201301). Written informed consent has been obtained from the patients to publish this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"589"}}